Abstract:Background and aims: Non communicable diseases including diabetes imposes substantial financial burden on households, societies and nations in both developed and developing countries. However, there is no information on the extent of diabetes expenditure in the Eastern Mediterranean Region (EMRO). Therefore, this study aimed to identify the treatment costs of diabetes in this area. To our knowledge, this is the first systematic review on treatment expenditures of diabetes in EMRO countries. Methods: A comprehensive literature search was conducted in PUBMED, MEDLINE, EMBASE, SCOPUS and WEB OF SCIENCES databases to find out published manuscripts on treatment cost of diabetes. Information was extracted using data extraction sheets and then the data were imported into STATA software version.11. Mean annual treatment cost of diabetes per patient, annual treatment costs of diabetes per patient by Diabetes Mellitus (DM) complications and finally, cost of chronic diabetes complications per patient were pooled and reported. Results: After reviewing title, abstract and the full text of identified articles; a total of seven studies were reported appropriate data for this meta-analysis. The pooled annual treatment cost per diabetes patient for EMRO countries was 1150 US$ (95% CI: 595-2221) which was 3358 US$ (95% CI: 2200-5124) in EMRO countries except of Iran compared to 255 US$ (92-708) in Iran. The treatment cost of diabetes was higher in males, insulin-used and in the patient with family history of diabetes. The cost of diabetes was significantly increased with the duration of diabetes (P = 0.001) as well. According to the results, the largest share of costs is related to medication costs. Finally, the pooled average annual treatment cost per patient by diabetes mellitus complications was varied from 2828 US$ in the patients that have cerebrovascular disease complication to 7261 US$ in the patients with Stroke complication. Conclusions: This study demonstrated that the annual treatment cost of diabetes is varied within EMRO countries. Qatar and Iran have spent the highest and lowest cost for diabetes, respectively. This may be due to the large socioeconomic differences between countries and special conditions of them such as currency value in the region.

Economic burden of diabetic foot ulcer: a case of Iran

Study on status quo and influencing factors of self perceived burden (SPB)in patients with middle and high risk of diabetic foot

Clinical and behavioral factors associated with management outcome in hospitalized patients with diabetic foot ulcer

Epidemiological Insights into Diabetic Foot Amputation and its Correlates: A Provincial Study

Projection of Diabetes Population Size and Associated Economic Burden through 2030 in Iran: Evidence from Micro-Simulation Markov Model and Bayesian Meta-Analysis

Cost of treating diabetic foot ulcers in five different countries

Study to Evaluate the Pharmacoeconomics in Diabetic Foot Ulcer Management

Economic cost of diabetes in the Eastern Mediterranean region countries: A meta-analysis

Diabetic Foot Ulcer in Malaysia: Consensus on Treatment Patterns, Health Care Utilization and Cost

Characteristics and outcomes of diabetic foot ulcers treated with surgical debridement and standardized wound care

Out‐of‐pocket expenditure among patients with diabetic foot ulcer in a tertiary care hospital of south India: A cross‐sectional study

Prevalence and Medical Resource of Patients with Diabetic Foot Ulcer: A Nationwide Population-Based Retrospective Cohort Study for 2001–2015 in Taiwan

Economic Burden of Trauma-Related Injuries in Iran in 2019

Losing a foot versus losing a dollar; a systematic review of cost studies in diabetic foot complications

Current knowledge of morbidities and direct costs related to diabetic foot disorders: a literature review

The economic burden of prostate cancer in Iran: a cross-sectional cost-of-illness study

Economic burden of major depressive disorder: a case study in Southern Iran

The cost of diabetic foot ulcers and amputations to the National Health Service in England

Fast-Track Pathway: An Effective Way to Boost Diabetic Foot Care

DIABETIC FOOT AMONG INDIVIDUALS WITH DIABETES IN SAUDI ARABIA: A COMPREHENSIVE REVIEW

Economic burden of gastro-oesophageal reflux disease and dyspepsia: A community-based study